Loading
FAK is the kinase that tells a cell it is anchored to its surroundings, letting it survive, move and resist drugs. Defactinib, given with the RAF/MEK inhibitor avutometinib, removes that escape route in low-grade serous ovarian cancer; other FAK inhibitors are in trials in meningioma and solid tumours. This dossier gathers the 3 products (1 approved), 16 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
The corpus records frame FAK as a resistance node rather than a driver: LGSOC cells arrest and regress only when FAK is blocked alongside RAF-MEK, and NF2-deficient meningioma depends on FAK signalling once merlin is lost.
| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| Small molecule 3 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | A Phase 3 Multicenter, Randomized, Controlled, and Open-Label Study of IN10018 in Combination With D-1553 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | - | ||
| 3 | Planned | A Phase 3, Randomized, Positive Controlled, Open-Label and Multicenter Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | - | ||
RAMP 201 NCT04625270 | 2 | Positive | Recurrent low-grade serous ovarian cancer: avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor) | ORR 44%, median PFS 19.6 months in KRAS-mutant LGSOC. | |
Alliance A071401 NCT02523014 | 2 | Positive | Recurrent or progressive grade 1 to 3 meningioma with a somatic NF2 mutation: oral GSK2256098 750 mg twice daily until progression, as the FAK-inhibitor arm of a genomically guided Alliance phase 2 umbrella | Six-month progression-free survival 83% (10 of 12) in grade 1 and 33% (8 of 24) in grade 2 to 3 NF2-mutant meningioma; both cohorts met the trial's decision criterion for promising activity. | |
| 2 | Recruiting | A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | - | ||
| 2 | Recruiting | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | - | ||
| 2 | Recruiting | Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | - | ||
| 1/2 | Active | A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation | - | ||
| 1/2 | Recruiting | Phase IIa Study of HX009+IN10018 in Patients With Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated With or Without Standard Chemotherapy | - | ||
| 1/2 | Recruiting | A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC | - | ||
| 1/2 | Recruiting | A Phase Ib/II Clinical Trial to Evaluate the Anti-tumor Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Anti-PD-1/L1 Antibody and Chemotherapy as First-line Treatment in Extensive-stage Small Cell Lung Cancer | - | ||
| 1/2 | Recruiting | A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | - | ||
| 1/2 | Recruiting | A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018 in Combination With Standard Chemotherapy in Subjects With High-grade Serous Epithelial Ovarian Cancer | - | ||
| 1/2 | Recruiting | A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic Cancer | - | ||
| 1/2 | Planned | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study | - | ||
| 1/2 | Active | A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Combination With IN10018 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"FAK" OR ABSTRACT:"FAK" OR TITLE:"PTK2" OR ABSTRACT:"PTK2" OR TITLE:"FAK1" OR ABSTRACT:"FAK1" OR TITLE:"FADK" OR ABSTRACT:"FADK" OR TITLE:"focal adhesion kinase" OR ABSTRACT:"focal adhesion kinase" OR TITLE:"protein tyrosine kinase 2" OR ABSTRACT:"protein tyrosine kinase 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAK (PTK2), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/fak.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/fak.json. Licence CC BY-NC 4.0.